| Prodrug name : Telotristat etiprate |
| PDID : PDIDT015 |
| Activating enzyme : Esterase (R1) |
| Mode of activation : Hydrolysis |
| Target : Tryptophan hydroxylase [TPH1 and TPH2] (R1, R2) |
| Properties improved : Impermeability of blood–brain barrier |
| Structure | |
| Prodrug | Active compound |
 |
| Experimental solubility and lipophilicity |
| LogP : Na |
| External web links (WL) |
1) https://pubchem.ncbi.nlm.nih.gov/compound/Telotristat%20etiprate; 2) https://www.genome.jp/dbget-bin/www_bget?dr:D09975; 3) https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL3348963; 4) https://www.chemspider.com/Chemical-Structure.28189674.html; 5) https://en.wikipedia.org/wiki/Telotristat_ethyl |
| References (R) |
1) doi:10.4155/CLI.15.10; 2) Xermelo, INN-telotristat etiprate https://ec.europa.eu/health/documents/community-register/2017/20170918138652/anx_138652_en.pdf; 3) 208794Orig1s000, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208794Orig1s000ClinPharmR.pdf; 4) XERMELO (telotristat ethyl, https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208794s000lbl.pdf |